Viatris Inc. (VTRS)

Total return at 5 years: 7.5%/year = 5.0% appreciation + 2.5% dividend. The target price ($22) is ex-dividend; the $2 in dividends collected over 5 years are added separately.

By both methods, the value today (DCF $62 · Multiples $20) exceeds the market price ($18).

Today — fairly valued: at $18 trades ~12.7% below its value discounted to today (~$20); the discount is positive but does not reach the margin of safety we require (≥38%).

At 5 years — En valor: the target price ($22) plus dividends yield between the 4% floor and the 10% average return — a reasonable return, though without the margin of a great investment.

The bridge: the return at 5 years exceeds the risk-free rate (4.5%) — but the discount does not reach the required margin of safety (≥38%). To require a 15% annual return, it would need to be bought at ~$13.

Educational / informational. Does not constitute investment advice.

The inverse approach: instead of projecting growth to obtain the value, the market price ($18) is taken as given and it solves for what annual owner-earnings growth would need to hold for 5 years for the present value —at the method's rate (4.5%, no-growth terminal)— to equal that price. It is the disconfirmation test: the expectations the price already pays for, contrasted against the method's projection.

The market discounts less growth (-23.2%/year) than we project (2.0%/year) → if the base case holds, there is margin: perception is more pessimistic than the estimated reality.

That growth implies ~$0.8 bn of owner earnings in year 5 (vs ~$3.3 bn of our base case). It recalculates if the DCF assumptions are edited.

Year-by-year projection of the selected scenario. From each year, two versions of the flow are derived: growth FCF (operating flow − total capex, the cash surplus) and maintenance FCF (the owner earnings: what the business yields if it only sustains its capacity). Cash accumulates the retained surplus —what is not returned as dividend or buyback—, so that EV falls and multiples compress going forward. The valuation is done on NOPAT (EV/NOPAT). In edit mode, revenue, margins, capex, and exit multiples can be adjusted.

Viatris is valued at the enterprise level on EV/NOPAT over adjusted after-tax operating income, on the basis the company itself reconciles from the GAAP result, which excludes purchase intangible amortization, goodwill impairment, restructuring and litigation charges, and other non-recurring items. The GAAP result of the last three fiscal years (net income of US$54.7 million in 2023, a loss of US$634.2 million in 2024, and a loss of US$3,514.9 million in 2025) is dominated by two one-off events: the intangible amortization inherited from the 2020 combination with Mylan (US$2,470-2,581 million per year) and a US$2,936.8 million goodwill impairment recognized in the first quarter of 2025. Adjusted earnings, by contrast, show a profitable business in moderate decline: US$3,537.7 million (2023), US$3,192.4 million (2024), and US$2,769.3 million (2025), with a pickup to a US$2,945.6 million pace over the twelve months ended June 30, 2026 (H1 2026 US$1,502.6 million plus FY2025 US$2,769.3 million minus H1 2025 US$1,326.3 million). Year 1 of the base case anchors on the guidance raised on August 6, 2026 (revenue between US$14,550 and US$14,950 million, adjusted EPS between US$2.45 and US$2.59, both at the midpoint), the most recent of two consecutive guidance raises in 2026. The 17.5% tax rate comes from dividing the total tax effect of the 2025 non-GAAP reconciliation (US$737.5 million) by the pre-tax base adjustment item (US$7,021.7 million); the GAAP effective rate (4.1% in 2025) is an artifact of the goodwill impairment, largely non-deductible, against a large pre-tax loss, and is not used. The share count path (-1.5% annual, the same across all three scenarios) follows the net reduction observed between the 2023 average diluted shares (1,206.9 million) and the count at the close of the second quarter of 2026 (1,163.3 million).

Today's elevated multiple is the price of growth: if the business grows, the entry point cheapens on its own going forward (the metric grows while EV stays roughly flat). The exit multiple at 3 years is higher than the terminal at 5 years —at 3 years there is more growth still ahead—, so the value curve shows whether value creation is concentrated in the early or the later years. The required return is applied to the base scenario.

They are valued separately, with their own rationale, and are not incorporated into the base or the verdict (they are excess return). When assigning them value — in Editmode —, the total with optionalities updates live, without moving the base.

The verdict, the base CAGR, and the margin of safety are always calculated on the base; optionalities do not alter them (with optionalities at $0 they do not move).

Each card fixes a required annual return and answers: if the business is worth $22 in 5 years, what is the maximum that can be paid today to obtain that return? Since it now trades at $18, the margin of safety is how much cheaper the market is than that maximum. The three thresholds: 4% covers inflation (the floor), 10% is the long-term average return, and 15% is the level of a great investment.

With a target price of $22 in 5 years plus $2 of dividends collected (the dividend adds to the return, not to the price) and a required return of 4.5% annually, the maximum to pay today is $20. Against the current market price ($18), the margin of safety is 12.7% (trades below the maximum → there is margin) and the total return at that price would be 7.5% annually.

• Entry multiple. Trades near the floor of the generic-pharma band, reflecting the low growth and eroding moat.
• Risk in the price. The market price already incorporates much of the restructuring execution risk.
• Dividend without growth. The dividend per share has stayed fixed at US$0.48 since 2022, contributing no growth to total return.

Each margin over sales, year by year: historical (solid line) → projection (dotted).

• ✕ ROIC exceeds the cost of capital (~10%)
• ✓ CFROIC backs up the ROIC (159%, cash vs. accruals)
• ✕ Healthy balance sheet (low corporate debt)
• ✓ Durable competitive moat (multiple advantages)

• Cash generation. Positive TTM free cash flow (approximately US$1,955 million) despite the negative GAAP result from impairments.
• Return on capital. Compressed by the goodwill inherited from the 2020 merger with Mylan; expected below the 10% bar.
• Reinvestment runway. The pipeline of innovative products is nascent, and maintenance capex (approximately US$376 million TTM) is low relative to the scale of the business.

Annual levels from the official filing (10-K); the % over each bar is the year-over-year (YoY) growth vs the prior year.

Viatris' driver is volume by price by product line: the branded business loses volume and price simultaneously as exclusivity expires, while generics competes on volume under structural pricing pressure (China, Medicare). The new-product ramp and the Indore plant recovery are the incremental drivers for 2026; there is no contracted backlog equivalent in this business, so the company's own guidance is the best available anchor for year 1.

The % are the annual (year-over-year) growth: each year —historical and projected— vs the prior one; the TTM (trailing 12m) vs the TTM of a year ago, to avoid overlapping windows. The historicals are exact figures from the official filings; the projected years come from the year-by-year model (the intermediate years without their own series are interpolated between the anchors). The projected columns (+1y…+5y) are 12-month windows counted from the TTM close (30-jun-2026): the projection starts from the most recently reported data, not the fiscal year. The projected base is realistic and unbiased — the risk discount is applied at the end, via the required return. The rationale for each metric is in the (i).

• Raised guidance. The company raised guidance across all metrics on August 6, 2026, the second time in the year.
• Declining base. Revenue fell in 2023, 2024, and 2025 before stabilizing in 2026.
• New products. US$450-550 million guided for 2026, still a small fraction of total sales.

• Manufacturing scale. 27 owned plants across five continents mitigate supply risk.
• Customer concentration. Cencora represents 11% of 2025 consolidated net sales.
• Loss of exclusivity. Adjusted earnings per share fell from US$2.93 (2023) to US$2.35 (2025) from price and volume pressure.
• Geographic diversification. Four geographic segments, with Greater China as the recent growth engine.

Not all debt is equal: only the structural needs refinancing; the rest is operational (self-liquidating).

Structural debt is what is exposed to the contraction phase of the cycle; operational debt (leases, matched funding) self-liquidates with the business.

• ✓Leverage (net debt / EBITDA)Net cash $0 bn
• ✓Interest coverage (EBIT / interest)8.3x
• –Liquidity (current ratio)no data
• ✓Cash quality (CFROIC vs ROIC)CFROIC backs 159% of ROIC
• ✕Value creation (ROIC − 10% bar)-5pp
• ✓Malinvestment test (capex vs incremental ROIC)Capex/D&A 0.1x — no over-investment
• !Float / working capitalConsumes cash $0.7 bn (positive WC)
• ✓Dilution (SBC % of revenue + shares)SBC 1.2% of revenue

A traffic-light interpreted by the method (not generic): float (negative WC) adds up, capex is judged by incremental ROIC (malinvestment test), and a lender is not subjected to corporate solvency. The (i) shows the derivation of each number.

• Leverage. 2.9x adjusted EBITDA as of June 30, 2026, within the 2.8-3.2 times target.
• Cash and liquidity. Cash and short-term investments below US$1,000 million against total debt exceeding US$13,300 million.
• Free cash flow. Positive and sufficient to cover the dividend and part of the buyback without additional debt.

• Deleveraging. Gross leverage brought down to 2.9x adjusted EBITDA following the sale of Biocon and disciplined capital allocation.
• Restructuring execution. The EWSR plan has only just started to show results; full savings are not yet confirmed.
• Ownership transparency. The DEF 14A proxy could not be parsed in this pass; ownership detail is declared as pending.

• Goodwill impairment and restructuring charges of more than US$3,000 million over the last three fiscal years sank the GAAP result, even as adjusted earnings and cash flow remained positive: a case of motivated sellers reacting to GAAP noise, not to the value of the business.
• The generics and off-patent branded pharma sector has less analyst coverage relative to innovative pharma, and the Indore plant regulatory problem generated a negative headline that may have been over-discounted relative to the real size of the impact (approximately US$370 million against US$14,250 million in sales).
• The company completed a series of divestitures (biosimilars, women's healthcare, API, over-the-counter) between 2022 and 2024 that simplified the business while the market remained anchored on the complexity of the previous holding structure.

Guidance raised twice in a row in 2026 and the reduction of leverage to 2.9 times are evidence that the business is stabilizing faster than the current price reflects.

The annual return (CAGR at 5 years) in each scenario, with the total period return below — the margin of safety made visual: upside range wide, downside range narrow.

Even in the bear scenario, the return holds at -9%/year (-38% total): the margin of safety protects the downside. The bull (+18%/year, +131% total) exceeds it comfortably — a favorable asymmetry, with a narrow downside range and a wide upside range.

• Regulatory (Indore). Active FDA import alert on 11 products, with reinspection not expected until 2026.
• Loss of exclusivity. Several branded products without patent protection face growing generic competition.
• Restructuring execution. The US$600-700 million in annual savings depend on a headcount reduction of up to 10% still underway.
• Regulatory pricing pressure. China's volume-based procurement system and Medicare price negotiation compress margin simultaneously.

Each thinker's analytical framework applied to our data.

• Buffett / Graham Quality + margin of safety

  Fails the quality gate: narrow moat, eroding.

• Peter Lynch Growth at a reasonable price (GARP)

  A slow grower growing 2% at a multiple/growth of 5.0 → expensive for its growth.

• Joel Greenblatt Cheap and high-return (Magic Formula)

  Earnings yield 20% (EBIT/EV) + ROIC 5% → falls outside the Magic Formula.

• Howard Marks Perception vs reality + cycle

  The price discounts -23% vs our 2%: perception is more pessimistic than reality, with an identified source of the discount.

• Seth Klarman Capital protection (bear scenario)

  Bear-scenario floor -13%/yr over 5y (material loss) → risk of permanent capital loss.

• Pat Dorsey Moat strength (Five Rules)

  A narrow moat, eroding; sources: efficient scale, intangibles, cost advantage → fails the Five Rules.

• Aswath Damodaran Expectations implied by the price

  Justifying the price requires discounting -23%, within what we project (2%) — the story squares with the numbers.